Lv21
164 积分 2023-01-29 加入
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
5小时前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
5小时前
已完结
HER3: Updates and current biology function, targeted therapy and pathologic detecting methods
12天前
已完结
Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma
12天前
已完结
Expression of EGFR, PD‐L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high‐grade serous tubo‐ovarian carcinoma
13天前
已完结
EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development
20天前
已完结
Preclinical and Clinical Development of Exatecan (DX-951f)
26天前
已完结
Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise
26天前
已完结
Recent Advances in Peptide Linkers for Antibody-Drug Conjugates
1个月前
已完结
Targeting the devil: Strategies against cancer-associated fibroblasts in colorectal cancer
1个月前
已完结
皖公网安备34019202002308
